Back to search

National and Kapodistrian University of Athens

Η επίδραση της ανασυνδυασμένης ερυθροποιητίνης (δαρβεποετίνης-α) στην εξέλιξη της καρδιακής ανεπάρκειας σε ασθενείς με χρόνια καρδιακή ανεπάρκεια και αναιμία

Abstract

dc:description

Introduction: Anemia often coexist with the syndrome of heart failure and leads to a worse prognosis. The administration of erythropoietin in these patients has been found to restore hemoglobin levels and improves exercise capacity. Aim: This study investigates the effect of an erythropoietin analogue, darbepoetin alfa in the correction of anemia, cardiac function and exercise capacity, neurohormonal profile, oxidative and nitrosative stress and additional quality of life and depressive symptoms in anemic patients with heart failure. Methods: 41 patients with heart failure (NYHA II III, left ventricular ejection fraction <40%, hemoglobin (Hb) <12,5 g/dl, plasma creatinine <2,5 mg/dl) were randomized to receive three months treatment with darbepoetin alfa (1,5 μg/kg) or placebo every 20 days. All patients received iron orally. Before and after the treatment the following parameters were studied: • Correction of anemia, a general biochemical profile. • Echocardiography assessment (systolic and diastolic function of left and right ventricle). • Neurohormonal profile of the patients BNP, CRP, TNF a, IL 1, IL 6, IL 10, SFas, sFas L, ICAM, VCAM, Oxidative stress (malondyalde (MDA), glutathione, protein carbonyls, nitrotyrosin). • Ability to exercise. • Quality of life and emotional stress with specific quality of life questionnaires (Kansas City Cardiomyopathy Questionnaire KCCQ και Duke's Activity Status Index DASI), and psychological mood (Zung Self rating Depression Scale SDS and Beck Depression Inventory BDI). Results/Conclusions: The administration of darbepoetin a, for a short period of time, seems to be an effective and safe therapeutic option for the correction of anemia, and improves cardiac function and exercise capacity, and neurohormonal profile in anemic patients with heart failure. Also, it appears that treatment with darbepoetin has antiapoptotic actions and improves markers of oxidative stress and nitrosative stress in these patients and additionally improves the quality of life and depressive symptoms.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2010

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kourea, Kallirrhoe
  • Κουρέα, Καλλιρρόη

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/25388

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kourea, Kallirrhoe; Κουρέα, Καλλιρρόη. Η επίδραση της ανασυνδυασμένης ερυθροποιητίνης (δαρβεποετίνης-α) στην εξέλιξη της καρδιακής ανεπάρκειας σε ασθενείς με χρόνια καρδιακή ανεπάρκεια και αναιμία. National and Kapodistrian University of Athens, 2010. http://hdl.handle.net/10442/hedi/25388